MIRA INFORM REPORT
|
Report No. : |
342810 |
|
Report Date : |
24.09.2015 |
IDENTIFICATION DETAILS
|
Name : |
AKUMS DRUGS AND PHARMACEUTICALS LIMITED |
|
|
|
|
Registered
Office : |
304, Mohan Place, LSC, Saraswati Vihar, New Delhi-110 034 |
|
Tel. No.: |
91-11-47511000 |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as
on) : |
31.03.2014 |
|
|
|
|
Date of
Incorporation : |
19.04.2004 |
|
|
|
|
Com. Reg. No.: |
55-125888 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs. 11.750 Million |
|
|
|
|
CIN No.: [Company Identification
No.] |
U24239DL2004PLC125888 |
|
|
|
|
IEC No.: |
0505004429 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
DELA13882B |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAECA7090B |
|
|
|
|
Legal Form : |
A Closely Held Public Limited Liability Company |
|
|
|
|
Line of Business
: |
Subject undertakes contract manufacturing of
formulations. |
|
|
|
|
No. of Employees
: |
3000 (Approximately) |
RATING & COMMENTS
|
MIRA’s Rating : |
A (63) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
USD 15000000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well-established company having fine track. The rating factors in the steady growth in revenue base stable profitability and strong cash accruals reported by the company which has resulting in a healthy financial risk profile. Fundamentals are strong and healthy. Overall financial position of the company is appears to be decent. In view of experienced management in pharmaceutical industry backed by healthy financials, the company can be considered for normal business dealings with usual trade terms and conditions |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
EXTERNAL AGENCY RATING
|
Rating Agency Name |
ICRA |
|
Rating |
Long term rating: A+ |
|
Rating Explanation |
Adequate degree of safety and low credit risk. |
|
Date |
April 2015 |
|
Rating Agency Name |
ICRA |
|
Rating |
Short term rating: A1+ |
|
Rating Explanation |
Very strong degree of safety and carry lowest credit risk. |
|
Date |
April 2015 |
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2015.
INFORMATION PARTED BY
|
Name : |
Mr. Sanjay Agarwal |
|
Designation : |
General Manager Accounts and Finance |
|
Contact No.: |
91-11-47511000 |
|
Date : |
24.09.2015 |
LOCATIONS
|
Registered Office / Corporate Office : |
304, |
|
Tel. No.: |
91-11-47511000 (30 lines) |
|
Fax No.: |
91-11-27023256 |
|
E-Mail : |
|
|
Website : |
|
|
Area: |
3000 Sq ft |
|
Location: |
Owned |
|
Locality: |
Commercial |
|
|
|
|
Manufacturing Unit I |
13,19,20,21,22,47,48 Sector-6A, I.I.E., SIDCUL, Ranipur,
Haridwar - 249403, Uttarakhand India |
|
Tel. No.: |
91-1334-239220 – 224, 325982, 84, 85,86 |
|
Fax No.: |
91-1334-239219 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Manufacturing Unit II |
22, Sector-6A, IIE, SIDCUL, Ranipur, Haridwar - 249403 Uttarakhand, India |
|
Tel. No.: |
91-1334-239220 – 224, 325982, 84 ,85, 86 |
|
Fax No.: |
91-1334-239219 |
|
E-Mail : |
|
|
|
|
|
Manufacturing Unit III |
2,3,4,5 Sector-6B, IIE, SIDCUL, Ranipur, Haridwar - 249403
|
|
Tel. No.: |
91-1334- 237100 – 104 |
|
Fax No.: |
91-1334-237105 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Manufacturing Unit IV : |
47, Sector 6B, SIDCUL, Ranipur, Haridwar - 249403 |
|
|
|
|
Manufacturing Unit V : |
48, Sector 6B, SIDCUL, Ranipur, Haridwar - 249403 |
|
|
|
|
Manufacturing Unit VI : |
13, Sector – 6A, SIDCUL, Intergrated Industrial Estate
Ranipur, Haridwar – 249403, |
DIRECTORS
AS ON 07.09.2014
|
Name : |
Mr. Sandeep Jain |
|
Designation : |
Whole-time director |
|
Address : |
E-1052, Saraswati Vihar, Delhi - 110034, India |
|
Date of Birth/Age : |
05.08.1967 |
|
Qualification : |
B.Com MBA FMSPI AMIMA |
|
Date of Appointment : |
01.06.2012 |
|
Voter ID No.: |
DL/03/018/273693 |
|
DIN No.: |
00323476 |
|
|
|
|
Name : |
Mr. Narendra Dev Sachdeva |
|
Designation : |
Whole-time director |
|
Address : |
40/22,IIIRD Floor, C R Park, Delhi - 110019, India |
|
Date of Birth/Age : |
15.10.1950 |
|
Qualification : |
B Pharma (Hons) |
|
Date of Appointment : |
01.04.2012 |
|
DIN No.: |
00330005 |
|
PAN No.: |
AYZPS4234M |
|
|
|
|
Name : |
Mr. Sanjeev Jain |
|
Designation : |
Whole-time director |
|
Address : |
E-1052, Saraswati Vihar, Delhi - 110034, India |
|
Date of Birth/Age : |
11.04.1966 |
|
Qualification : |
MBBS (BIO) MBA |
|
Date of Appointment : |
01.06.2012 |
|
Voter ID No.: |
DL/03/018/273610 |
|
DIN No.: |
00323433 |
|
PAN No.: |
AAAPJ1891Q |
|
|
|
|
Name : |
Mr. Nand Lal Kalra |
|
Designation : |
Additional director |
|
Address : |
4 BA 11, Jawahar Nagar, Jaipur - 302004, Rajasthan, India |
|
Date of Birth/Age : |
05.02.1950 |
|
Date of Appointment : |
01.06.2012 |
|
DIN No.: |
05268554 |
KEY EXECUTIVES
|
Name : |
Mr. Dharamvir Malik |
|
Designation : |
Secretary |
|
Address : |
RZ/A-1/20, 2nd Floor, Mahavir Enclave, Near Bank Of
Baroda,, New Delhi, 110045, India |
|
Date of Birth/Age : |
21.06.1983 |
|
Date of Appointment : |
01.04.2014 |
|
PAN No: |
AQPPM7439Q |
|
|
|
|
Name : |
Mr. Sanjay Aggarwal |
|
Designation : |
Chief Finance Officer |
|
Address : |
House No. CU-118, Pitampura, Delhi - 110034, India |
|
Date of Appointment : |
24.08.2014 |
|
PAN No: |
ACAPA8516H |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
AS ON 07.09.2014
|
Names of Shareholders |
No. of Shares |
|
Sanjeev Jain |
585275 |
|
Lata Jain |
75 |
|
Sanjeev Jain Joint with Arushi Jain |
300 |
|
Lata Jain Joint with Umang Jain |
50 |
|
Sanjeev Jain Joint with Kiran Jain |
1800 |
|
Sandeep Jain |
585350 |
|
Sandeep Jain Joint with Kanishk Jain |
300 |
|
Manan Jain U/G Sandeep Jain |
50 |
|
Sandeep Jain Joint with Kiran Jain |
1800 |
|
Total |
1175000 |
Equity Share Break up (Percentage of Total Equity)
AS ON 07.09.2014
|
Category |
Percentage |
|
Directors or relatives of Directors |
100.00 |
|
Total |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Subject undertakes contract manufacturing of
formulations. |
||||
|
|
|
||||
|
Products : |
|
||||
|
|
|
||||
|
Brand Names : |
Not Available |
||||
|
|
|
||||
|
Agencies Held : |
Not Available |
||||
|
|
|
||||
|
Exports : |
|
||||
|
Products : |
Finished Goods |
||||
|
Countries : |
|
||||
|
|
|
||||
|
Imports : |
|
||||
|
Products : |
Raw Material |
||||
|
Countries : |
|
||||
|
|
|
||||
|
Terms : |
|
||||
|
Selling : |
L/C, Cash and Credit |
||||
|
|
|
||||
|
Purchasing : |
L/C, Cash and Credit |
PRODUCTION STATUS (As on 31.03.2013)
|
Particulars |
Nos |
Installed Capacity |
Production |
|
Tablets |
Nos. |
2884 Crs |
110,350,625 |
|
Capsules |
Nos. |
555 Crs |
11,000,356 |
|
Dry Syrups |
Nos. |
24 Crs |
338,483 |
|
Liquid Oral |
Nos. |
8.20 Crs |
48 |
|
Liquid Oral |
Kilo Ltrs |
28,080 |
50 |
|
Dry Powder and Liquid Injection |
Nos. |
107.54 Crs |
2,696,112 |
|
Eye/Ear Drops(SVP) |
Nos. |
10.8 Crs |
1,462,628 |
|
Infusion Bottles(LVP) |
Nos. |
2.33 Crs |
193,321 |
|
Pre-filled Syringes |
Nos. |
2.24Crs |
-- |
|
Cosmetic Products |
Kgs |
59,04,000 |
4,643 |
Installed capacity has been certified by the Company, this being a technical matter.
GENERAL INFORMATION
|
Suppliers : |
|
||||||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
Customers : |
Wholesalers, Retailers
|
||||||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
No. of Employees : |
3000 (Approximately) |
||||||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
Bankers : |
Standard Chartered Bank, Credit Risk Control, Narain Manzil, 23 Barakhamba Road, New Delhi - 110001, India
|
||||||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
Facilities : |
(Rs.
In Million)
|
|
Auditors : |
|
|
Name : |
Anil Jain D.D and Company Chartered Accountant |
|
Address : |
611, |
|
PAN N Income-tax PAN of auditor or auditor's firm : |
AARFA8414D |
|
|
|
|
Memberships : |
Not Available |
|
|
|
|
Collaborators : |
Not Available |
|
|
|
|
Subsidiary Company: |
|
|
|
|
|
Enterprises which are
owned, or have significant influence of or are partners with Key Management personnel and their relatives: |
|
CAPITAL STRUCTURE
AS ON 31.03.2014
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
1200000 |
Equity shares |
Rs.10/- each |
Rs. 12.000 Million |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
1175000 |
Equity shares |
Rs.10/- each |
Rs. 11.750 Million |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in Rupees Million]
ABRIDGED
BALANCE SHEET
|
SOURCES
OF FUNDS |
31.03.2014 |
31.03.2013 |
31.03.2012 |
|
|
|
|
|
|
I.
EQUITY AND LIABILITIES |
|
|
|
|
(1)Shareholders' Funds |
|
|
|
|
(a) Share Capital |
11.750 |
11.750 |
11.750 |
|
(b) Reserves & Surplus |
5359.833 |
4299.884 |
3469.074 |
|
(c) Money received against
share warrants |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
(2) Share Application money
pending allotment |
0.000 |
0.000 |
0.000 |
|
Total
Shareholders’ Funds (1) + (2) |
5371.583 |
4311.634 |
3480.824 |
|
|
|
|
|
|
(3) Non-Current Liabilities |
|
|
|
|
(a) long-term borrowings |
15.123 |
68.600 |
115.943 |
|
(b) Deferred tax liabilities
(Net) |
234.976 |
205.656 |
213.790 |
|
(c) Other long term
liabilities |
22.671 |
18.980 |
15.060 |
|
(d) long-term provisions |
201.850 |
192.949 |
10.394 |
|
Total
Non-current Liabilities (3) |
474.620 |
486.185 |
355.187 |
|
|
|
|
|
|
(4) Current Liabilities |
|
|
|
|
(a) Short term borrowings |
1245.165 |
436.092 |
1196.363 |
|
(b) Trade payables |
1110.556 |
1079.863 |
787.996 |
|
(c) Other current liabilities |
258.372 |
253.962 |
272.301 |
|
(d) Short-term provisions |
52.544 |
59.039 |
26.655 |
|
Total
Current Liabilities (4) |
2666.637 |
1828.956 |
2283.315 |
|
|
|
|
|
|
TOTAL |
8512.840 |
6626.775 |
6119.326 |
|
|
|
|
|
|
II.
ASSETS |
|
|
|
|
(1) Non-current assets |
|
|
|
|
(a) Fixed Assets |
|
|
|
|
(i) Tangible assets |
2554.277 |
2578.221 |
2397.658 |
|
(ii) Intangible Assets |
42.450 |
28.788 |
28.020 |
|
(iii) Capital work-in-progress |
0.000 |
6.997 |
112.352 |
|
(iv) Intangible assets under
development |
0.000 |
0.000 |
0.000 |
|
(b) Non-current Investments |
44.397 |
12.050 |
6.150 |
|
(c) Deferred tax assets (net) |
0.000 |
0.000 |
0.000 |
|
(d) Long-term Loan and Advances |
2031.161 |
1218.135 |
522.053 |
|
(e) Other Non-current assets |
0.000 |
0.000 |
0.000 |
|
Total
Non-Current Assets |
4672.285 |
3844.191 |
3066.233 |
|
|
|
|
|
|
(2) Current assets |
|
|
|
|
(a) Current investments |
0.000 |
0.000 |
0.000 |
|
(b) Inventories |
1608.615 |
1110.488 |
1203.254 |
|
(c) Trade receivables |
1911.317 |
1578.479 |
1217.327 |
|
(d) Cash and cash equivalents |
211.548 |
28.863 |
4.641 |
|
(e) Short-term loans and
advances |
109.075 |
64.754 |
627.871 |
|
(f) Other current assets |
0.000 |
0.000 |
0.000 |
|
Total
Current Assets |
3840.555 |
2782.584 |
3053.093 |
|
|
|
|
|
|
TOTAL |
8512.840 |
6626.775 |
6119.326 |
PROFIT
& LOSS ACCOUNT
|
|
PARTICULARS |
31.03.2014 |
31.03.2013 |
31.03.2012 |
|
|
SALES |
|
|
|
|
|
Income |
8966.357 |
7939.537 |
6496.314 |
|
|
Other Income |
212.866 |
160.846 |
121.430 |
|
|
TOTAL
(A) |
9179.223 |
8100.383 |
6617.744 |
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
Cost of Materials Consumed |
6121.779 |
5408.489 |
4366.087 |
|
|
Changes in inventories of
finished goods, work-in-progress and Stock-in-Trade |
(33.781) |
(46.901) |
68.054 |
|
|
Employees benefits expense |
916.685 |
757.364 |
651.073 |
|
|
Other expenses |
548.499 |
484.569 |
431.512 |
|
|
Exceptional items |
0.000 |
175.228 |
0.000 |
|
|
TOTAL
(B) |
7553.182 |
6778.749 |
5516.726 |
|
|
|
|
|
|
|
Less |
PROFIT/
(LOSS) BEFORE INTEREST, TAX,
DEPRECIATION AND AMORTISATION (C) |
1626.041 |
1321.634 |
1101.018 |
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
76.518 |
113.362 |
124.719 |
|
|
|
|
|
|
|
|
PROFIT
/ (LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
1549.523 |
1208.272 |
976.299 |
|
|
|
|
|
|
|
Less/
Add |
DEPRECIATION/
AMORTISATION (F) |
143.542 |
127.947 |
109.837 |
|
|
|
|
|
|
|
|
PROFIT/ (LOSS)
BEFORE TAX (E-F) (G) |
1405.981 |
1080.325 |
866.462 |
|
|
|
|
|
|
|
Less |
TAX (H) |
349.033 |
249.515 |
179.076 |
|
|
|
|
|
|
|
|
PROFIT/ (LOSS)
AFTER TAX (G-H) (I) |
1056.948 |
830.810 |
687.386 |
|
|
|
|
|
|
|
|
Earnings
/ (Loss) Per Share (Rs.) |
900.00 |
707.00 |
141.065 |
|
Particulars |
|
|
31.03.2015 |
|
Sales Turnover (Approximately) |
|
|
9700.000 |
Expected Sales (2015-2016) : Rs.5000.000 Million
The above information has been parted by Mr. Sanjay Agarwal
CURRENT MATURITIES
OF LONG TERM DEBT DETAILS
|
Particulars |
31.03.2014 |
31.03.2013 |
31.03.2012 |
|
Current Maturities of Long term debt |
60.490 |
54.880 |
51.530 |
|
Cash generated from operations |
NA |
NA |
NA |
|
Net cash flows from (used in) operations |
753.489 |
1530.302 |
1086.708 |
KEY
RATIOS
|
PARTICULARS |
|
31.03.2014 |
31.03.2013 |
31.03.2012 |
|
Net Profit Margin (PAT / Sales) |
(%) |
11.79 |
10.46 |
10.58 |
|
|
|
|
|
|
|
Operating Profit Margin (PBIDT/Sales) |
(%) |
18.13 |
16.65 |
16.95 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
16.60 |
16.35 |
14.44 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.26 |
0.25 |
0.25 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Debt /Networth) |
|
0.25 |
0.13 |
0.39 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
1.44 |
1.52 |
1.34 |
FINANCIAL ANALYSIS
[all figures are
in Rupees Million]
DEBT EQUITY RATIO
|
Particular |
31.03.2012 |
31.03.2013 |
31.03.2014 |
|
|
(Rs.
In Million) |
(Rs.
In Million) |
(Rs.
In Million) |
|
Share Capital |
11.750 |
11.750 |
11.750 |
|
Reserves & Surplus |
3469.074 |
4299.884 |
5359.833 |
|
Money received against share
warrants |
0.000 |
0.000 |
0.000 |
|
Share Application money pending allotment |
0.000 |
0.000 |
0.000 |
|
Net
worth |
3480.824 |
4311.634 |
5371.583 |
|
|
|
|
|
|
long-term borrowings |
115.943 |
68.600 |
15.123 |
|
Short term borrowings |
1196.363 |
436.092 |
1245.165 |
|
Current maturities of
long-term debts |
51.530 |
54.880 |
60.490 |
|
Total
borrowings |
1363.836 |
559.572 |
1320.778 |
|
Debt/Equity
ratio |
0.392 |
0.130 |
0.246 |
YEAR-ON-YEAR GROWTH
|
Year
on Year Growth |
31.03.2012 |
31.03.2013 |
31.03.2014 |
|
|
(Rs.
In Million) |
(Rs.
In Million) |
(Rs.
In Million) |
|
Sales |
6496.314 |
7939.537 |
8966.357 |
|
|
|
22.216 |
12.933 |
NET PROFIT MARGIN
|
Net
Profit Margin |
31.03.2012 |
31.03.2013 |
31.03.2014 |
|
|
(Rs.
In Million) |
(Rs.
In Million) |
(Rs.
In Million) |
|
Sales |
6496.314 |
7939.537 |
8966.357 |
|
Profit |
687.386 |
830.810 |
1056.948 |
|
|
10.58% |
10.46% |
11.79% |
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check list by
info agents |
Available in
Report (Yes/No) |
|
1 |
Year of establishment |
Yes |
|
2 |
Constitution of the entity -Incorporation
details |
Yes |
|
3 |
Locality of the entity |
Yes |
|
4 |
Premises details |
Yes |
|
5 |
Buyer visit details |
-- |
|
6 |
Contact numbers |
Yes |
|
7 |
Name of the person contacted |
Yes |
|
8 |
Designation of contact person |
Yes |
|
9 |
Promoter’s background |
Yes |
|
10 |
Date of Birth of Proprietor / Partners /
Directors |
Yes |
|
11 |
Pan Card No. of Proprietor / Partners |
Yes |
|
12 |
Voter Id Card No. of Proprietor / Partners |
No |
|
13 |
Type of business |
Yes |
|
14 |
Line of Business |
Yes |
|
15 |
Export/import details (if applicable) |
Yes |
|
16 |
No. of employees |
Yes |
|
17 |
Details of sister concerns |
Yes |
|
18 |
Major suppliers |
Yes |
|
19 |
Major customers |
Yes |
|
20 |
Banking Details |
Yes |
|
21 |
Banking facility details |
Yes |
|
22 |
Conduct of the banking account |
-- |
|
23 |
Financials, if provided |
Yes |
|
24 |
Capital in the business |
Yes |
|
25 |
Last accounts filed at ROC, if applicable |
Yes |
|
26 |
Turnover of firm for last four years |
Yes |
|
27 |
Reasons for variation <> 20% |
-- |
|
28 |
Estimation for coming financial year |
Yes |
|
29 |
Profitability for last three years |
Yes |
|
30 |
Major shareholders, if available |
Yes |
|
31 |
External Agency Rating, if available |
Yes |
|
32 |
Litigations that the firm/promoter
involved in |
-- |
|
33 |
Market information |
-- |
|
34 |
Payments terms |
Yes |
|
35 |
Negative Reporting by Auditors in the
Annual Report |
No |
PHARMA INDUSTRY STRUCTURE
AND DEVELOPMENTS:
India is now among the top five pharmaceutical emerging markets. The Indian pharma industry has been growing at a compounded annual growth rate (CAGR) of more than 15 per cent over the last five years and has significant growth opportunities.
The industry, particularly, has been the front runner in a wide range of specialties involving complex drugs' manufacture, development, and technology. With the advantage of being a highly organized sector, number of pharmaceutical companies are increasing their operations in India.
The pharmaceutical industry in India is an extremely fragmented market with severe price competition and government price control. The pharmaceutical industry in India is highly regulated.
FUTURE OUTLOOK
Recent studies conducted about Indian Pharmaceutical Market by USA India Chamber of commerce, Mckinsey and Company, CII- PwC India and Ernest and Young reveal that Indian Pharmaceutical Market will grow double from current year’s $18 billion to over $45 billion by the year 2020
· India will be top three Pharma market by incremental growth by 2020 (in terms of quantity)
· India will be sixth largest market globally in absolute size by 2020 (in terms of money)
· Only USA, China, Japan, Germany will be ahead of India in global Pharma.
· Accounts for over 8% of the global pharmaceutical production.
· Over 60,000 Generic brands across 60 therapeutic categories.
· Manufactures / Uses for production, more than 500 different APIs
· India market is fragmented with more than 1000 players and 60,000 brands.
· Two third of market will be in top cities
· Middle class consumer segment will be key determining fact.
· India has comparative cost advantage; because of low production costs.
Pharma production costs in India are 65% lower than US and European manufacturers
· RandD boosts efficiencies; Innovation, Quality and Services are big assets of India
· Costs of Clinical trials in India is cheaper
· Over 120 US FDA approved facilities ? highest number of US FDAs in the world.
· 37% production is out sourced by Pharma companies from CRAMS.
OUTLOOK:
Akums dedicates itself to humanity’s quest for longer, healthier, happier lives through innovation in pharmaceuticals formulations. Their mission is to remain demanding on the highest ethical standards, making their products and processes of the highest quality and; also being committed to meeting the needs of their customers, and constantly focus on customer satisfaction.
Akums has excellent future and they are expecting a growth rate much higher to the world’s pharma growth. Akums has eight plants, fully functional; other two are for R and D and Formulation development, Centralized Warehousing and stability study chambers. Akums foresees to serve top pharmaceuticals companies of globe and to have global manufacturing plants. Akums wants to lead the world of Manufacturing in virtually every area of Healthcare and wants to be of the top companies in Manufacturing of Pharmaceuticals.
Akums believes that GOD has given us an opportunity to serve the human beings by providing care and cure through excellent medicines. With the change in lifestyle, the demand for medicines is bound to grow, either for prevention or for cure of diseases. Pharma Industry is resistant to economic slowdown. Akums business Model is designed to innovate patient friendly medicines of best quality. The business model of Akums is unique. It has demonstrated as to how a contract manufacturer has become a necessity for big Pharma houses of the country. The growth of Akums has brought prosperity to human beings and the persons working for the organization either as employees or as suppliers or as buyers.
Akums has brought over all growth inside and outside. Akums has brought for the country a sense of quality medicines. AKUMS is not merely a contract manufacturing company but a Technology Driven and Research Oriented Organization with lot of Innovative Formulations and dosage forms in its product range. Pharmaceutical innovation is a vital part of improving and saving lives around the world. New medicines have revolutionized medical practice in the past century leading to incredible health improvements. Indirectly, innovative medicines do not only benefit patients but are an important element of well-functioning of overall healthcare systems. They bring novel solutions to resolve different health problems in order to improve lives and overall well being of humanity across the globe.
INDEX
OF CHARGES
|
S.NO. |
CHARGE ID |
DATE OF CHARGE
CREATION/MODIFICATION |
CHARGE AMOUNT
SECURED |
CHARGE HOLDER |
ADDRESS |
SERVICE REQUEST
NUMBER (SRN) |
|
1 |
10556644 |
01/09/2015 * |
300,000,000.00 |
STANDARD CHARTERED INVESTMENTS AND LOANS (INDIA) L |
FLOOR NO. 6, CRESCENZO BUILDING, C-38/39,, "G"
BL |
C63041800 |
|
2 |
10217825 |
01/09/2015 * |
150,000,000.00 |
STANDARD CHARTERED BANK |
CREDIT RISK CONTROL, NARAIN MANZIL, 23 BARAKHAMBA |
C62976972 |
|
3 |
10019466 |
30/01/2012 * |
1,500,000,000.00 |
STATE BANK OF INDIA |
COMMERCIAL BRANCH,, M-47, CONNAUGHT CIRCUS,, NEW |
B32485583 |
* Date of charge modification
FIXED ASSETS
Tangible assets
- Land
- Buildings
- Plant and equipment
- Furniture and fixtures
- Vehicles
- Office equipment
Intangible assets
- Brands and trade marks
- Licenses and franchise
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts, India Prisons Service,
Interpol, etc.
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international anti-terrorism
laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper payments
to government officials for engaging in prohibited transactions or with
designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record exists
to suggest that any director or indirect owners, controlling shareholders,
director, officer or employee of the company is a government official or a
family member or close business associate of a Government official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws, regulations
or policies that prohibit, restrict or otherwise affect the terms and
conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.65.97 |
|
UK Pound |
1 |
Rs.101.19 |
|
Euro |
1 |
Rs.73.38 |
INFORMATION DETAILS
|
Information
Gathered by : |
DIP |
|
|
|
|
Analysis Done by
: |
KIN |
|
|
|
|
Report Prepared
by : |
KVT |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
7 |
|
PAID-UP CAPITAL |
1~10 |
6 |
|
OPERATING SCALE |
1~10 |
7 |
|
FINANCIAL
CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
7 |
|
--PROFITABILITY |
1~10 |
8 |
|
--LIQUIDITY |
1~10 |
7 |
|
--LEVERAGE |
1~10 |
7 |
|
--RESERVES |
1~10 |
7 |
|
--CREDIT LINES |
1~10 |
7 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
DEFAULTER |
|
|
|
--RBI |
YES/NO |
NO |
|
--EPF |
YES/NO |
NO |
|
TOTAL |
|
63 |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.